SARS-CoV-2 RNA in blood
This dataset provides supplementary material for a report of the prevalence of SARS-CoV-2 RNA in blood and blood products.
Extended Data File 1: Metadata table providing data for prevalence of SARS-CoV-2 RNA in blood and blood products based on a systematic literature review. Details of 28 citations are presented, and the 22 studies included in quantitative meta-analysis are indicated.
Extended Data File 2: qRT-PCR quantification of vRNA from sera and viral culture assays. Calculation of vRNA copy numbers, and qRT-PCR results in figure and table format.
Underlying Data File 1: Metadata table providing underlying data for serum samples from adults with confirmed SARS-CoV-2 infection, based on RT-PCR nose/throat swab. Sheet 1: samples obtained through patients recruited into a UK clinical cohort at Oxford University Hospitals NHS Foundation Trust (n=212 samples from 167 unique individuals). Cells highlighted in blue show follow-up samples collected from the same individual at different time points. Cells highlighted in orange show serum PCR positives. Sheet 2: samples obtained from convalescent donors a minimum of 28 days post resolution of symptoms, via NHS Blood and Transplant, NHSBT (n=142 samples from 142 individuals).
RT-PCR Primer sequences: provided in a .xlsx file.
PRISMA checklist: reporting for systematic review and meta-analysis
STROBE checklist: reporting for cohort studies
Fig 4A-D: raw, unedited microscope images of cell cultures. Dates of each image stored in the format YYYYMMDD.
(A) and (B) are controls:
(A) Negative control Vero E6 cells in media;
(B) Cytopathic effect (CPE) in Vero E6 cells spiked with Victoria/01/2020 SARS-CoV-2.
(C) and (D) are Vero E6 cells inoculated with 1/10 dilution of serum sample from sample VC12 (patient ID UKCOV040), that tested positive for SARS-CoV-2 RNA by RT-PCR:
(C) Aberrant cellular effects at day 4 in a culture inoculated with VC12 at day 0;
(D) Normal appearance of cells at day 7 inoculated with 1/10 dilution of the culture supernatant of the VC12-challenged culture, illustrated in (C).
